ArticleFrontiers in nutrition2026
Reduced circulating STOX1 is associated with inflammatory cytokines and insulin resistance in obese individuals: a cross-sectional study.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Excess adiposity drives adipose tissue dysfunction and metabolic disease, including type 2 diabetes and cardiovascular disorders. Building on our prior GEO-based analyses that nominated Storkhead box 1 (STOX1) as a candidate biomarker of obesity-related adipose inflammation, we compared circulating STOX1 between individuals with normal weight and those with overweight/obesity and examined its metabolic correlates. Methods: In 476 volunteers, we quantified serum STOX1, adipokines, and clinical parameters; we further contrasted STOX1 and adiponectin between groups and performed an oral glucose tolerance test (OGTT) to assess glycemic effects on STOX1. Results: Serum STOX1 was significantly lower in overweight/obese (OW/OB) participants than controls (controls: 1.27 ± 1.40 µg/L; OW/OB: 0.69 ± 0.77 µg/L; Discussion: During OGTT, hyperglycemia suppressed circulating STOX1, suggesting glucose-dependent regulation of its secretion/release. Collectively, these findings indicate that decreased serum STOX1 tracks adverse metabolic and inflammatory profiles in obesity and support its potential utility as a noninvasive biomarker of adipose tissue inflammation in overweight/obese individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.